STOCKHOLM - November 12, 2025 - Inify Laboratories AB ("Inify" or the "Company")
will in a separate press release call for an extraordinary general meeting (the
"EGM") to be held on December 4, 2025 at 10:00 CET to resolve on afully
guaranteed share issue of a total of 28,571,429 new shares generating gross
proceeds of approximately NOK 100 million.

The board of directors' reasons for proposing the equity issue are to ensure
financial stability and persistence. This is due to a slight delay in the fit
-out project and larger-than-expected investments related to the establishment
in the UK. This, in combination with insight of lengthy processes to convene
business with the public healthcare sector has led the board of directors to
decide to finance the expansion through equity.

The proposed issue of shares will be divided into two tranches with (i) a fully
guaranteed private placement of approximately NOK 92 million with a minimum
subscription per subscriber of the NOK equivalent of EUR 100,000 directed pro
-rata towards existing shareholders holding more than 1,000,000 shares in the
Company (the "Private Placement"), and (ii) a fully guaranteed repair issue of
approximately NOK 8 million (the "Repair Issue"), directed pro-rata towards
existing shareholders that did not participate in the Private Placement and who
hold less than 1,000,000 shares in the Company. For technical reasons, the
shares in the Private Placement and the Repair Issue will be issued at nominal
value to SB1 Markets AS ("SB1 Markets") to be allocated to shareholders who have
applied for shares in the share issues, at the subscription price. The
subscription price per share in the Private Placement and the Repair Issue will
be NOK 3.50 per share.

The basis for the subscription price is the market value of the share together
with what the board of directors considers to be a market conformant discount,
corresponding to what would be applied to the subscription price in a rights
issue. The reason for not applying the shareholders' pre-emption rights is to
reduce the costs for the Company which would otherwise be associated with a
rights issue. As only shareholders in the Company will be able to participate,
on a pro-rata basis, in the Private Placement and the Repair Issue, as
applicable. Shareholders are, however, expected to be able to maintain their pro
-rata shareholding in the Company after the Private Placement and the Repair
Issue, as long as such shareholders submit an application corresponding to their
pro-rata shareholding in the Company.

MonsunAS and Auris AS(the "Guarantors"), companies controlled by the same owners
as the two largest shareholdersGallivantS.àr.l. and Tauri AS, respectively, have
entered into guarantee undertakings covering in total 100% of the Private
Placement and the Repair Issue (the "Guarantee Commitment"). The Guarantors will
not receive any compensation for the Guarantee Commitment.

Application period for Private Placement

The application period for the Private Placement is proposed to commence on 9
December 2025, and to end on 16 December 2025 at 16:30 hours CET (the "Private
Placement Application Period"). The board of directors will have the right to
extend or shorten the Private Placement Application Period at any time and for
any reason on short, or without, notice. If the Private Placement Application
Period is extended or shortened, the other dates referred to herein might be
changed accordingly.

Record date and application period for the Repair Issue

The Repair Issue is proposed, subject to applicable securities law, to be
directed towards all existing shareholders in the Company, other than the
shareholders eligible to take part in the Private Placement, as of 16 December
2025 (as registered in Euronext Securities Oslo (the "VPS") or Euroclear, as
applicable, on 18 December 2025 (the "RecordDate")), who are not resident in a
jurisdiction where such offering would be unlawful or would (in jurisdictions
other than Norway) require any prospectus, filing, registration or similar
action.

Provided that the EGM resolves to carry out the Repair Issue, the Company will,
if required, publish a national (Norwegian) prospectus in the beginning of
January 2026 and thereafter commence the two-week application period for the
Repair Issue (the "Repair Issue Application Period"). Shareholders with shares
registered with the VPS as of the Record Date is intended to receive non
-transferable subscription rights, which they will then receive at the start of
the Repair Issue Application Period. Shareholders with shares registered
directly with Euroclear as of the Record Date will not receive any subscription
rights. Instead, such shareholders will receive an application form which shall
be used to apply for subscription for shares in the Repair Issue.

The key dates for the Repair Issue are set out below:

  · Last day of trading in the Company's shares including the right to
participate in Repair Issue: 16 December 2025
  · Ex-date: 17 December 2025
  · Record date: 18 December 2025
  · Repair Issue Application Period: on or around 12 January 2026 - 26 January
2026.

Settlement

The date for payment of the Private Placement and the Repair Issue is expected
to be on or about 16 February 2026 (the "Payment Date"). The new shares in the
Private Placement and the Repair Issue are expected to be delivered on or about
19 February 2026, subject to turnaround time for registration of the share
capital increasesrelating to the Private Placement and the Repair Issue with the
Swedish Companies Registration Office ("SCRO"). The shares allocated in the
Private Placement and the Repair Issue will be tradable on Euronext Growth Oslo
when the new shares have been registered with the SCRO and registered by
Euroclear Sweden and VPS, respectively, expected on or about 19 February 2026.

Commencement of the Private Placement and the Repair Offering is subject to
approval by the EGM.

For further information, please contact CEO, Fredrik Palm,
[email protected],or visit
https://www.inify.com (https://protect.checkpoint.com/v2/r02/___https://www.inif
y
.com___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3OjFj
M
TM6YjE3M2Q4MTI2YmQxZjEyYzJmYWVhMzdlYWFiMTNiZGVlMjdkZjA1MjdlMTNjN2JlOTMyYmNkZDZmN
z
ViNjhhMjpwOlQ6VA)

Advisors

SB1 Markets has been appointed as financial advisor in connection with the
Private Placement and the Repair Issue. Schjødt law firm acts as legal counsel
to the Company.

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo(https://live.euronext.com/en/product/equities/SE0017486103
-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwt
i
zhydjvznynjxdXJ556a9b*~*658
-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc
3
NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZl
O
TE5NmJhMjpwOlQ6VA)) under the ticker
INIFY.(https://live.euronext.com/en/product/equities/SE0017486103
-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwt
i
zhydjvznynjxdXJ556a9b*~*658
-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc
3
NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZl
O
TE5NmJhMjpwOlQ6VA))

###

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading
Act.

This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify
Laboratories AB on the time and date provided.

###

Important information

The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in the Company in any jurisdiction. Any invitation to the persons
concerned to subscribe for shares in the Repair Issue will only be made through
the national (Norwegian) prospectus which the Company expects to publish in the
beginning of January 2026.

This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and Repair Issue must be made on the basis of all publicly available
information relating to the Company and the Company's shares. Such information
has not been independently verified by SB1 Markets. The information contained in
this announcement is for background purposes only and does not purport to be
full or complete. No reliance may be placed for any purpose on the information
contained in this announcement or its accuracy or completeness. SB1 Markets is
acting for the Company in connection with the transaction and no one else and
will not be responsible to anyone other than the Company for providing the
protections afforded to its clients nor for giving advice in relation to the
transaction or any other matter referred to herein.

This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and Repair Issue. Each
investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.

The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Swedish law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.

No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.

Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.

In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order")